Palisade Bio, Inc. (PALI) — S-1 Filings
All S-1 filings from Palisade Bio, Inc.. Browse 3 IPO Filing reports with AI-powered summaries and risk analysis.
S-1 Filings (3)
-
Palisade Bio Seeks Capital After Positive PALI-2108 Phase 1 Results
— Sep 29, 2025 Risk: high
Palisade Bio, Inc. (PALI) is a clinical-stage biopharmaceutical company focused on autoimmune, inflammatory, and fibrotic diseases, with its lead product candid -
Palisade Bio Files S-1 for Public Offering, Signaling Capital Raise
— May 27, 2025 Risk: high
Palisade Bio, Inc. (PALI) filed an S-1 registration statement on May 27, 2025, for a proposed public offering of securities, indicating a continuous offering pu -
Palisade Bio Files S-1 for Potential Securities Offering
— Oct 30, 2024 Risk: medium
Palisade Bio, Inc. filed an S-1 registration statement on October 30, 2024, to register an unspecified number of securities. The company, formerly known as Sene
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX